Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)Renato Bassan, Alessandro Rambaldi, Giuseppe Rossi et al.|Blood|2009Cited by 433
Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groupsRenato Bassan, Tiziano Barbui, Enrico Pogliani et al.|The Hematology Journal|2001Cited by 33
Should alpha interferon be used as primary treatment for hairy cell leukemia?Giovanni Capnist, E Damasio, Massimo Federico et al.|Leukemia Research|1991Cited by 9